Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

At median follow-up of 13.2 months, tafasitamab, an investigational monoclonal antibody directed against CD19, in combination with lenalidomide resulted in a high proportion of patients having an objective response (n=161; 60%; 43% complete response; 18% partial response).


The Lancet Oncology